Kunkel Lori Anne's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Jul 8, 2026
- Accession no.
- 0001536368-26-000007
- Filed
- Jul 8, 2026, 5:15 PM ET
- Trade date
- Jul 6, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $504.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kunkel Lori AnneCIK 0001536368 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | Common Stock | SSaleDisposed | −4,111 | $49.98 | −$205,481.76 | 47,773 | Direct | |
| Jul 6, 2026 | Common Stock | SSaleDisposed | −5,889 | $50.84 | −$299,421.49 | 41,884 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.